Payment overview · 2025
General Payments
$967.85
59 reported records · 17 companies
Healthcare provider profile · identity verified
Gregory Scott Phillips, MD
Allopathic & Osteopathic Physicians|Family Medicine · SIBLEY, LA · NPI 1497743413
Verified facts
What the public records show
CMS Open Payments records show Gregory Scott Phillips, MD received $967.85 in general payments during 2025 across 59 reported records.
ABBVIE INC. accounted for 16.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Linzess, Mounjaro, Nexletol, Ozempic, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Farxiga by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLETOL as an associated drug or biological on 24230 records involving 12642 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nexletol by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 337 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 75 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 340 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $158.25 | 16.4% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $156.12 | 16.1% | 13 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $142.04 | 14.7% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $90.75 | 9.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $78.43 | 8.1% | 4 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $49.68 | 5.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.44 | 5.0% | 3 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $36.81 | 3.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $36.25 | 3.8% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.94 | 3.2% | 2 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $29.20 | 3.0% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.68 | 2.0% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.65 | 2.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.44 | 2.0% | 1 | 2025 |
| Antares Pharma, Inc. | Unresolved — no canonical attribution shown | $18.02 | 1.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.56 | 1.8% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.59 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $967.85 | 59 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $156.12 | 13 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $156.12 | 13 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $104.55 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $90.75 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $88.63 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $64.81 | 3 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $49.68 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.59 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $36.81 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $36.25 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $31.42 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $30.94 | 2 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $29.20 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $25.03 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.76 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $19.68 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.48 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| XYOSTED Normalized: xyosted |
Drug | Antares Pharma, Inc. | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $18.01 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.89 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 49 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 240 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 46 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 337 | exact normalized | Medicare Part D |
| NEXLETOL nexletol |
2025 | Nexletol | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 340 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 144 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
46 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
49 | 12 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLETOL open payments reported associated product |
CMS Open Payments — General Payments 24230 supporting records · 12642 recipient NPIs · example record 1243949989 |
Nexletol · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
144 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
240 | 62 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
337 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
75 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
340 | 55 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 908 | 244 |
| Losartan Potassium | Losartan Potassium | 707 | 182 |
| Gabapentin | Gabapentin | 694 | 181 |
| Amlodipine Besylate | Amlodipine Besylate | 638 | 164 |
| Pantoprazole Sodium | Pantoprazole Sodium | 585 | 146 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 483 | 131 |
| Omeprazole | Omeprazole | 470 | 122 |
| Duloxetine Hcl | Duloxetine Hcl | 435 | 95 |
| Lisinopril | Lisinopril | 423 | 114 |
| Levothyroxine Sodium | Levothyroxine Sodium | 419 | 104 |
| Potassium Chloride | Potassium Chloride | 398 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 389 | 92 |
| Furosemide | Furosemide | 380 | 111 |
| Clopidogrel | Clopidogrel Bisulfate | 346 | 90 |
| Metformin Hcl Er | Metformin Hcl | 345 | 93 |
| Ozempic | Semaglutide | 340 | 55 |
| Mounjaro | Tirzepatide | 337 | 45 |
| Metoprolol Succinate | Metoprolol Succinate | 317 | 79 |
| Prednisone | Prednisone | 316 | 198 |
| Metoprolol Tartrate | Metoprolol Tartrate | 314 | 77 |
| Hydrochlorothiazide | Hydrochlorothiazide | 293 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 288 | 122 |
| Alprazolam | Alprazolam | 288 | 68 |
| Metformin Hcl | Metformin Hcl | 256 | 71 |
| Sertraline Hcl | Sertraline Hcl | 253 | 61 |
| Trazodone Hcl | Trazodone Hcl | 247 | 66 |
| Jardiance | Empagliflozin | 240 | 62 |
| Fluticasone Propionate | Fluticasone Propionate | 230 | 108 |
| Meloxicam | Meloxicam | 217 | 60 |
| Eliquis | Apixaban | 213 | 44 |
| Famotidine | Famotidine | 212 | 64 |
| Montelukast Sodium | Montelukast Sodium | 212 | 72 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 208 | 147 |
| Azithromycin | Azithromycin | 202 | 149 |
| Pravastatin Sodium | Pravastatin Sodium | 199 | 54 |
| Allopurinol | Allopurinol | 197 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 187 | 48 |
| Cefdinir | Cefdinir | 182 | 131 |
| Carvedilol | Carvedilol | 159 | 41 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 144 | 30 |
| Simvastatin | Simvastatin | 139 | 38 |
| Atenolol | Atenolol | 138 | 38 |
| Glipizide Er | Glipizide | 138 | 34 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 138 | 36 |
| Methocarbamol | Methocarbamol | 133 | 45 |
| Tramadol Hcl | Tramadol Hcl | 129 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 124 | 26 |
| Quetiapine Fumarate | Quetiapine Fumarate | 120 | 29 |
| Clonidine Hcl | Clonidine Hcl | 111 | 42 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 110 | 28 |
| Pregabalin | Pregabalin | 110 | 23 |
| Buspirone Hcl | Buspirone Hcl | 108 | 24 |
| Fluconazole | Fluconazole | 108 | 57 |
| Celecoxib | Celecoxib | 105 | 33 |
| Clonazepam | Clonazepam | 102 | 21 |
| Mirtazapine | Mirtazapine | 102 | 16 |
| Naproxen | Naproxen | 93 | 39 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 91 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 89 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 86 | 64 |
| Zolpidem Tartrate | Zolpidem Tartrate | 84 | 18 |
| Risperidone | Risperidone | 83 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 79 | 20 |
| Glipizide | Glipizide | 78 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 34 |
| Trulicity | Dulaglutide | 75 | 16 |
| Enalapril Maleate | Enalapril Maleate | 74 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 73 | 47 |
| Pioglitazone Hcl | Pioglitazone Hcl | 73 | 18 |
| Ezetimibe | Ezetimibe | 72 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 17 |
| Nifedipine Er | Nifedipine | 67 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 19 |
| Entresto | Sacubitril/Valsartan | 65 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 13 |
| Meclizine Hcl | Meclizine Hcl | 64 | 36 |
| Sucralfate | Sucralfate | 64 | 21 |
| Bumetanide | Bumetanide | 63 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 63 | 25 |
| Methylprednisolone | Methylprednisolone | 63 | 49 |
| Nebivolol Hcl | Nebivolol Hcl | 63 | 17 |
| Tresiba Flextouch U-200 | Insulin Degludec | 63 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 29 |
| Donepezil Hcl | Donepezil Hcl | 61 | 18 |
| Lovastatin | Lovastatin | 61 | 16 |
| Mupirocin | Mupirocin | 61 | 34 |
| Ibandronate Sodium | Ibandronate Sodium | 60 | 21 |
| Chlorthalidone | Chlorthalidone | 58 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 57 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 56 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Primidone | Primidone | 53 | 15 |
| Colchicine | Colchicine | 52 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 15 |
| Valsartan | Valsartan | 52 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 51 | 14 |
| Farxiga | Dapagliflozin Propanediol | 49 | 12 |
| Estradiol | Estradiol | 48 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 30 |
| Doxazosin Mesylate | Doxazosin Mesylate | 46 | 13 |
| Linzess | Linaclotide | 46 | 11 |
| Nitroglycerin | Nitroglycerin | 46 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 36 |
| Synthroid | Levothyroxine Sodium | 45 | suppressed |
| Ibuprofen | Ibuprofen | 44 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 44 | suppressed |
| Digoxin | Digoxin | 43 | suppressed |
| Finasteride | Finasteride | 42 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 38 | suppressed |
| Glimepiride | Glimepiride | 38 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 37 | 31 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | 15 |
| Bupropion Xl | Bupropion Hcl | 33 | 11 |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Lorazepam | Lorazepam | 33 | suppressed |
| Nystatin | Nystatin | 33 | 21 |
| Xarelto | Rivaroxaban | 32 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Baclofen | Baclofen | 30 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 30 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 30 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 30 | suppressed |
| Rybelsus | Semaglutide | 30 | 11 |
| Temazepam | Temazepam | 30 | suppressed |
| Tradjenta | Linagliptin | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 29 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 17 |
| Spironolactone | Spironolactone | 29 | 11 |
| Topiramate | Topiramate | 29 | 11 |
| Estradiol (Twice Weekly) | Estradiol | 28 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 28 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Valacyclovir | Valacyclovir Hcl | 25 | 22 |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 12 |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 23 | suppressed |
| Ciclopirox | Ciclopirox | 23 | 16 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Erythromycin | Erythromycin Base | 22 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 21 | suppressed |
| Humulin R | Insulin Regular, Human | 21 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Diazepam | Diazepam | 20 | 11 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 20 | 20 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Repatha Sureclick | Evolocumab | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 18 | suppressed |
| Ofloxacin | Ofloxacin | 18 | 15 |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 18 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 17 | suppressed |
| Amoxicillin | Amoxicillin | 17 | 12 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Novolin R | Insulin Regular, Human | 17 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Ibu | Ibuprofen | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Bicalutamide | Bicalutamide | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Metronidazole | Metronidazole | 15 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Nexletol | Bempedoic Acid | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Levemir | Insulin Detemir | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 12 | suppressed |
| Glyburide | Glyburide | 12 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Probenecid | Probenecid | 12 | suppressed |
| Rinvoq | Upadacitinib | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $967.85 · 59 records | ABBVIE INC. | ABRYSVO, AIRSUPRA, BREZTRI, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, GEMTESA, JARDIANCE, JATENZO, Kerendia, LINZESS, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, QULIPTA, REPATHA, TONMYA, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, XYOSTED, ZAVZPRET, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error